These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14657601)

  • 1. Forced expression of cytidine deaminase confers sensitivity to capecitabine.
    Morita T; Matsuzaki A; Kurokawa S; Tokue A
    Oncology; 2003; 65(3):267-74. PubMed ID: 14657601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    Morita T; Matsuzaki A; Tokue A
    Int J Cancer; 2001 May; 92(3):451-6. PubMed ID: 11291085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.
    Yasuno H; Kurasawa M; Yanagisawa M; Sato Y; Harada N; Mori K
    Oncol Rep; 2013 Feb; 29(2):451-8. PubMed ID: 23229803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
    Saif MW; Kang SP; Ledbetter L; Steg A; Diasio R; Johnson M
    JOP; 2007 Nov; 8(6):799-805. PubMed ID: 17993734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
    Ribelles N; López-Siles J; Sánchez A; González E; Sánchez MJ; Carabantes F; Sánchez-Rovira P; Márquez A; Dueñas R; Sevilla I; Alba E
    Curr Drug Metab; 2008 May; 9(4):336-43. PubMed ID: 18473752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy.
    Chung YL; Troy H; Judson IR; Leek R; Leach MO; Stubbs M; Harris AL; Griffiths JR
    Clin Cancer Res; 2004 Jun; 10(11):3863-70. PubMed ID: 15173095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
    Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
    Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential].
    Stepanova EV; Bokhian BIu; Petrovichev NN; Lichinitzer MR
    Vopr Onkol; 2005; 51(3):314-6. PubMed ID: 16279094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
    Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
    Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
    Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
    Guichard SM; Macpherson JS; Mayer I; Reid E; Muir M; Dodds M; Alexander S; Jodrell DI
    Eur J Cancer; 2008 Jan; 44(2):310-7. PubMed ID: 18077151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study.
    Garcia AA; Blessing JA; Lenz HJ; Darcy KM; Mannel RS; Miller DS; Husseinzadeh N;
    Gynecol Oncol; 2005 Mar; 96(3):810-7. PubMed ID: 15721430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
    Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
    Neff T; Blau CA
    Exp Hematol; 1996 Sep; 24(11):1340-6. PubMed ID: 8862446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Ouchi KF; Yanagisawa M; Sekiguchi F; Tanaka Y
    Cancer Chemother Pharmacol; 2006 May; 57(5):693-702. PubMed ID: 16362295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
    Ninomiya I; Terada I; Yoshizumi T; Takino T; Nagai N; Morita A; Fushida S; Nishimura G; Fujimura T; Ohta T; Miwa K
    Int J Cancer; 2004 Oct; 112(1):135-42. PubMed ID: 15305385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.
    Di Gennaro E; Piro G; Chianese MI; Franco R; Di Cintio A; Moccia T; Luciano A; de Ruggiero I; Bruzzese F; Avallone A; Arra C; Budillon A
    Br J Cancer; 2010 Nov; 103(11):1680-91. PubMed ID: 21045833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.